Receptor News and Research

RSS

Scientists develop preclinical model of scrub typhus disease

Scientists have developed an animal model of scrub typhus using outbred CD-1 mice. Using the model, they have characterized host susceptibility to the causative pathogen, disease pathogenesis, and immune responses. The study has been published in the journal PLOS Neglected Tropical Diseases.

27 Nov 2022

People who belong to blood group Rh(D) have elevated risk of parvovirus infection

The risk of being infected by parvovirus is elevated in those people who have blood group Rh(D), according to a study published in The Journal of Infectious Diseases by researchers from Karolinska Institutet in Sweden in collaboration with Octapharma.

25 Nov 2022

Scientists investigate the evolutionary origin of SARS-CoV-2 using recombination-aware phylogenetic analysis

A study has employed Bacter to identify recombination events with the RBD regions of the Sarbecovirus genome.

25 Nov 2022

Single drug compound may offer a promising new strategy for treating prostate cancer patients

A single drug compound simultaneously attacks hard-to-treat prostate cancer on several fronts, according to a new study in mice and human cells.

23 Nov 2022

Study suggests the behavior of an emergent SARS-CoV-2 variant may be sensitive to the immunologic and demographic context of its location

Researchers characterized the heterogeneity in the speed, magnitude, and timing of 13 SARS-CoV-2 variant transitions/waves.

23 Nov 2022

Over 440 SCI articles published! BGI’s cancer genetics and cell research fuels innovation

BGI has currently published over 440 SCI (Science Citation Index) papers in the field of cancer research, with a cumulative impact factor of over 4,000 points.

From BGI Genomics 23 Nov 2022

The safety and immunogenicity of a fourth dose of NVX-CoV2373

Researchers assessed the immunogenicity and safety of a fourth homologous boost dose of a recombinant SARS-CoV-2 spike protein vaccine called NVX-CoV2373.

23 Nov 2022

The binding and functional serologic responses to COVID-19 vaccination in children with history of MIS-C

Researchers evaluated the serological responses elicited by COVID-19 vaccinations in children who developed MIS-C following a previous SARS-CoV-2 infection.

23 Nov 2022

New York sewer rats are easily infected by SARS-CoV-2, according to new study

Researchers evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure among rats inhabiting New York City (NYC) during the fall of 2021.

23 Nov 2022

Plant-based monoclonal antibody increases potency of antibody cocktail against SARS-CoV-2 Omicron variant

A novel mAb against the SARS-CoV-2 RBD through a hybridoma technique, followed by chimerization and expression in plants.

22 Nov 2022

SARS-CoV-2 seroprevalence in domestic cats has increased over time

Researchers evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission among domestic cats in the United Kingdom (UK).

22 Nov 2022

Proteomic analysis identifies novel phenotypes associated with COVID-19 severity in circulating immune cells

In a recent study, researchers used proteomic analysis to identify novel immune cell phenotypes associated with severe coronavirus disease 2019 (COVID-19).

22 Nov 2022

Cancer Research Horizons, Newcastle University extend strategic drug discovery alliance with Astex Pharmaceuticals

Cancer Research UK’s newly launched innovation engine, Cancer Research Horizons, and Newcastle University, have announced a further significant extension of their strategic drug discovery alliance with Astex Pharmaceuticals (UK) (‘Astex’), a biotechnology company dedicated to the discovery and development of novel small molecule therapeutics.

22 Nov 2022

Study finds no benefits from angiotensin receptor blocker treatment for COVID-19

In a recent study published in the BMJ, researchers conducted a phase three, multicenter, randomized controlled trial to evaluate the effect of using angiotensin receptor blockers that disrupt the renin-angiotensin system on the clinical outcomes of individuals with coronavirus disease 2019 (COVID-19).

21 Nov 2022

Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients

A third COVID-19 vaccine dose in this patients with blood cancers could enhance their antibody responses against SARS-CoV-2

21 Nov 2022

Chitin-immobilized nanobodies for SARS-CoV-2 detection

Researchers demonstrated a novel strategy to detect SARS-CoV-2 using chitin-immobilized nanobodies.

21 Nov 2022

CAR T-cell therapy in colorectal cancer

Researchers assessed the efficacy of CAR T-cells in the immunotherapy of colorectal cancer.

21 Nov 2022

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

On November 17, 2022, the US Food and Drug Administration (FDA) approved a pathbreaking new drug called Tzield. This injectable formulation contains a combination of two drugs that could push back the onset of type 1 diabetes (T1D) in adults at stage 3 and children aged eight years or more at stage 2.

20 Nov 2022

Researchers uncover new therapeutic vulnerability in endocrine therapy-resistant breast cancers

For patients with estrogen receptor (ER)-positive breast cancer, development of the so-called Y537S mutation signals that their disease has taken an aggressive course and may become resistant to endocrine therapy.

20 Nov 2022

Novel molecular imaging radiotracer can precisely diagnose multiple cancers

A new molecular imaging radiotracer can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies.

20 Nov 2022

Receptor News and Research

Scientists develop preclinical model of scrub typhus disease

People who belong to blood group Rh(D) have elevated risk of parvovirus infection

Scientists investigate the evolutionary origin of SARS-CoV-2 using recombination-aware phylogenetic analysis

Single drug compound may offer a promising new strategy for treating prostate cancer patients

Study suggests the behavior of an emergent SARS-CoV-2 variant may be sensitive to the immunologic and demographic context of its location

Over 440 SCI articles published! BGI’s cancer genetics and cell research fuels innovation

The safety and immunogenicity of a fourth dose of NVX-CoV2373

The binding and functional serologic responses to COVID-19 vaccination in children with history of MIS-C

New York sewer rats are easily infected by SARS-CoV-2, according to new study

Plant-based monoclonal antibody increases potency of antibody cocktail against SARS-CoV-2 Omicron variant

SARS-CoV-2 seroprevalence in domestic cats has increased over time

Proteomic analysis identifies novel phenotypes associated with COVID-19 severity in circulating immune cells

Cancer Research Horizons, Newcastle University extend strategic drug discovery alliance with Astex Pharmaceuticals

Study finds no benefits from angiotensin receptor blocker treatment for COVID-19

Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients

Chitin-immobilized nanobodies for SARS-CoV-2 detection

CAR T-cell therapy in colorectal cancer

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

Researchers uncover new therapeutic vulnerability in endocrine therapy-resistant breast cancers

Novel molecular imaging radiotracer can precisely diagnose multiple cancers

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News